Condition: Atrial Fibrillation (AF) · Sponsor: Cardioangiologisches Centrum Bethanien
The proposed pilot study is a prospective, randomized, single-center feasibility study, enrolling 200 patients with symptomatic paroxysmal AF. Per protocol, 100 patients will undergo a FARAPULSE electroporation PVI and 100 patients will receive standard AF medical treatment. Prior enrollment, all patients will be informed on the risk and benefits of the PVI procedure as well as the medical treatment. In addition, particular information on the rationale of the study, including a detailed risk/benefit analysis, will be provided to all patients.
This description comes directly from the study's public registry record.
Julian Chun, Professor · +49 69 945028 · j.chun@ccb.de
Boris Scmidt, Professor · +49 69 945028 · b.schmidt@ccb.de
Always discuss trial participation with your own doctor first.
| Cardioangiologisches Centrum Bethanien | Frankfurt am Main, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07385417